TOLVAPTAN and DEATH

Overview

DEATH is the #1 most commonly reported adverse reaction for TOLVAPTAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 973 FDA adverse event reports linking TOLVAPTAN to DEATH. This represents approximately 4.0% of all 24,584 adverse event reports for this drug.

Patients taking TOLVAPTAN who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DEATH is moderately reported among TOLVAPTAN users, representing a notable but not dominant share of adverse events.

Other Side Effects of TOLVAPTAN

In addition to death, the following adverse reactions have been reported for TOLVAPTAN:

• OFF LABEL USE — 814 reports
• RENAL IMPAIRMENT — 804 reports
• CARDIAC FAILURE — 785 reports
• THIRST — 775 reports
• PRODUCT DOSE OMISSION ISSUE — 522 reports
• PRODUCT USE IN UNAPPROVED INDICATION — 487 reports
• WRONG TECHNIQUE IN PRODUCT USAGE PROCESS — 480 reports
• UNDERDOSE — 477 reports
• DEHYDRATION — 449 reports
• BLOOD CREATININE INCREASED — 422 reports

Other Drugs Associated with DEATH

The following drugs have also been linked to death in FDA adverse event reports:

Does TOLVAPTAN cause DEATH?

DEATH has been reported as an adverse event in 973 FDA reports for TOLVAPTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DEATH with TOLVAPTAN?

DEATH accounts for approximately 4.0% of all adverse event reports for TOLVAPTAN, making it one of the most commonly reported side effect.

What should I do if I experience DEATH while taking TOLVAPTAN?

If you experience death while taking TOLVAPTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages